AB2 Bio Ltd. news

• Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3
• Joins AB2 Bio from Novartis and has extensive commercial and strategic experience

AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO).

Dr Filipovic has more than 20 years of exper

• Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH)
• WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch

AB2 Bio Ltd., a Swiss advanced clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics (“WuXi Bio”) (2269.HK), a gl

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases including rare diseases with high unmet medical needs, announces the appointment of the experienced pharmaceutical executive Michael Soldan, PhD as its Chief Executive Officer.

Dr Soldan joins from global healthcare company Fresenius Kabi, where he was CEO of the Global Biosimilars Business located in Switzerland, r

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized withdrawal phase for its ongoing pivotal Phase 3 trial under an Investigational New Drug (IND) Application for its product candidate Tadekinig alfa, has been accepted by the U.S. Food and Drug Administration (FDA). Tadekinig alfa is a recombinant human i